JP2022511515A5 - - Google Patents
Info
- Publication number
- JP2022511515A5 JP2022511515A5 JP2021531985A JP2021531985A JP2022511515A5 JP 2022511515 A5 JP2022511515 A5 JP 2022511515A5 JP 2021531985 A JP2021531985 A JP 2021531985A JP 2021531985 A JP2021531985 A JP 2021531985A JP 2022511515 A5 JP2022511515 A5 JP 2022511515A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pyrimidine
- trifluoromethyl
- pyrazolo
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102890A JP2024150464A (ja) | 2018-12-20 | 2024-06-26 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783014P | 2018-12-20 | 2018-12-20 | |
| US62/783,014 | 2018-12-20 | ||
| US201962799423P | 2019-01-31 | 2019-01-31 | |
| US62/799,423 | 2019-01-31 | ||
| US201962857986P | 2019-06-06 | 2019-06-06 | |
| US62/857,986 | 2019-06-06 | ||
| US201962868616P | 2019-06-28 | 2019-06-28 | |
| US62/868,616 | 2019-06-28 | ||
| US201962946263P | 2019-12-10 | 2019-12-10 | |
| US62/946,263 | 2019-12-10 | ||
| PCT/US2019/067521 WO2020132269A1 (en) | 2018-12-20 | 2019-12-19 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102890A Division JP2024150464A (ja) | 2018-12-20 | 2024-06-26 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511515A JP2022511515A (ja) | 2022-01-31 |
| JP2022511515A5 true JP2022511515A5 (cg-RX-API-DMAC7.html) | 2022-12-26 |
| JP7662519B2 JP7662519B2 (ja) | 2025-04-15 |
Family
ID=71100912
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531985A Active JP7662519B2 (ja) | 2018-12-20 | 2019-12-19 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
| JP2024102890A Pending JP2024150464A (ja) | 2018-12-20 | 2024-06-26 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102890A Pending JP2024150464A (ja) | 2018-12-20 | 2024-06-26 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
Country Status (16)
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473495B (zh) | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| EP4161494A4 (en) * | 2020-06-02 | 2024-07-17 | KSQ Therapeutics, Inc. | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS |
| AU2021341895A1 (en) * | 2020-09-10 | 2023-04-06 | BBIT-Therapeutics, Lda. | New pharmaceutical compounds, methods and uses thereof |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| EP4291559A1 (en) * | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| WO2022197892A1 (en) * | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
| CA3214040A1 (en) * | 2021-04-07 | 2022-10-13 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| JP7652935B2 (ja) * | 2021-05-03 | 2025-03-27 | 山東軒竹医薬科技有限公司 | 三環式ユビキチン特異的プロテアーゼ１阻害剤及びその使用 |
| CN117412973A (zh) * | 2021-05-31 | 2024-01-16 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
| GB202114863D0 (en) | 2021-10-18 | 2021-12-01 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| US20240409538A1 (en) * | 2021-10-19 | 2024-12-12 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| CN114031556B (zh) * | 2021-11-08 | 2023-03-31 | 温州大学 | 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法 |
| IL312642A (en) * | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430041A4 (en) * | 2021-11-12 | 2025-09-24 | Insilico Medicine Ip Ltd | SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| CN114181237B (zh) * | 2021-12-01 | 2024-02-23 | 上海凌凯医药科技有限公司 | 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法 |
| AU2022405104A1 (en) * | 2021-12-09 | 2024-05-30 | KSQ Therapeutics, Inc. | Methods of preparing substituted pyrazolopyrimidines |
| WO2023143424A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
| US20250163049A1 (en) * | 2022-02-03 | 2025-05-22 | Exelixis, Inc. | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| WO2023155866A1 (zh) | 2022-02-18 | 2023-08-24 | 四川海思科制药有限公司 | 一种吡唑并吡啶衍生物及其在医药上的应用 |
| EP4504175A1 (en) * | 2022-04-08 | 2025-02-12 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents |
| CN116925098B (zh) * | 2022-04-09 | 2026-02-17 | 深圳湾实验室 | 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用 |
| KR20250004854A (ko) * | 2022-04-29 | 2025-01-08 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 피리미딘 화합물, 이의 제조 방법 및 이의 약학적 용도 |
| EP4543890A1 (en) * | 2022-06-23 | 2025-04-30 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
| US20240092779A1 (en) * | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
| WO2024032647A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| CN117263944B (zh) * | 2022-08-24 | 2025-10-17 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂及其用途 |
| CN119790043A (zh) * | 2022-08-26 | 2025-04-08 | 海南先声再明医药股份有限公司 | 三环类化合物及其应用 |
| WO2024046471A1 (zh) * | 2022-09-02 | 2024-03-07 | 上海齐鲁制药研究中心有限公司 | Usp1抑制剂 |
| CN119698417A (zh) * | 2022-09-09 | 2025-03-25 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物 |
| JP2025531133A (ja) * | 2022-09-20 | 2025-09-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体 |
| CN117384187B (zh) * | 2022-09-30 | 2026-01-30 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂 |
| WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| CN120202201A (zh) * | 2022-11-04 | 2025-06-24 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
| CN120513237A (zh) | 2023-01-12 | 2025-08-19 | 先正达农作物保护股份公司 | 除草咪唑化合物 |
| CN120603835A (zh) * | 2023-01-20 | 2025-09-05 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| TW202446392A (zh) * | 2023-04-27 | 2024-12-01 | 大陸商西藏海思科製藥有限公司 | 吡啶並吡唑衍生物的藥物組合物及其在醫藥上的應用 |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
| CN121219283A (zh) * | 2023-07-05 | 2025-12-26 | 江苏亚虹医药科技股份有限公司 | 联嘧啶化合物的晶型及其制备方法和用途 |
| KR20260033560A (ko) * | 2023-07-05 | 2026-03-10 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 피리미딘 화합물, 이의 제조 방법 및 이의 의학적 용도 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| WO2025015905A1 (en) * | 2023-07-14 | 2025-01-23 | Laekna Therapeutics Shanghai Co., Ltd. | Pyrimidine compounds and their use as usp1 inhibitors |
| TW202530229A (zh) * | 2023-09-26 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 氮雜環胺類化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| WO2025095751A1 (ko) * | 2023-10-30 | 2025-05-08 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| TW202535865A (zh) | 2023-10-31 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 泛素特異性加工蛋白酶1 (usp1) 化合物 |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025180502A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 一种联合用药物组合物及其用途 |
| WO2025193045A1 (ko) * | 2024-03-12 | 2025-09-18 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| WO1996023899A1 (en) | 1995-02-01 | 1996-08-08 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
| DK0934526T3 (da) | 1996-10-08 | 2003-05-05 | Bisys B V U | Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| WO2007149484A2 (en) | 2006-06-20 | 2007-12-27 | Dana-Farber Cancer Institute | Inhibitors of usp1 deubiquitinating enzyme complex |
| EP2092083A2 (en) | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
| US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| EP2209786B1 (en) * | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| AU2009222122A1 (en) * | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| JPWO2009157196A1 (ja) * | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| SG11201607586UA (en) * | 2014-03-13 | 2016-10-28 | Agency Science Tech & Res | Fused pyrimidine-based hydroxamate derivatives |
| KR101766194B1 (ko) * | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
| CN108473495B (zh) * | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| EP4291559A1 (en) | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2019
- 2019-12-19 US US16/721,079 patent/US11485736B2/en active Active
- 2019-12-19 MX MX2021007179A patent/MX2021007179A/es unknown
- 2019-12-19 AU AU2019405925A patent/AU2019405925B2/en active Active
- 2019-12-19 JP JP2021531985A patent/JP7662519B2/ja active Active
- 2019-12-19 CA CA3122108A patent/CA3122108A1/en active Pending
- 2019-12-19 SG SG11202106232TA patent/SG11202106232TA/en unknown
- 2019-12-19 PH PH1/2021/551402A patent/PH12021551402A1/en unknown
- 2019-12-19 EP EP19897934.6A patent/EP3897652A4/en active Pending
- 2019-12-19 TW TW108146728A patent/TWI834784B/zh active
- 2019-12-19 TW TW113105437A patent/TWI895986B/zh active
- 2019-12-19 WO PCT/US2019/067521 patent/WO2020132269A1/en not_active Ceased
- 2019-12-19 BR BR112021010715A patent/BR112021010715A2/pt unknown
- 2019-12-19 CN CN201980079551.2A patent/CN113164485A/zh active Pending
- 2019-12-19 IL IL284050A patent/IL284050B2/en unknown
- 2019-12-19 KR KR1020217017482A patent/KR102912147B1/ko active Active
-
2021
- 2021-06-16 CL CL2021001575A patent/CL2021001575A1/es unknown
- 2021-07-12 CO CONC2021/0009078A patent/CO2021009078A2/es unknown
-
2022
- 2022-10-11 US US18/045,770 patent/US11787813B2/en active Active
-
2024
- 2024-06-26 JP JP2024102890A patent/JP2024150464A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511515A5 (cg-RX-API-DMAC7.html) | ||
| IL284050B1 (en) | Modified pyrazolopyrimidines and modified purines and their use as 1 uso inhibitors | |
| US20240366608A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| JP2022184886A5 (cg-RX-API-DMAC7.html) | ||
| US20240366620A1 (en) | Compounds, compositions and methods for cancer patient stratification and cancer treatment | |
| JP7723666B2 (ja) | 環式化合物およびその使用方法 | |
| ES2573716T3 (es) | Compuestos de piridona y aza-piridona y métodos de utilización | |
| TWI622395B (zh) | 使用ｔｏｒ之激酶抑制劑之癌症治療 | |
| US10786492B2 (en) | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | |
| TWI635862B (zh) | 使用ｔｏｒ激酶抑制劑之癌症治療 | |
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| JP2013523884A5 (cg-RX-API-DMAC7.html) | ||
| KR20190046921A (ko) | 세포 대사 과정의 억제제 | |
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| EA032416B1 (ru) | Соединения триазолопиримидина и их применения | |
| AU6178899A (en) | Method of treating nitrate-induced tolerance | |
| HUE032770T2 (en) | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders | |
| WO2018153968A1 (en) | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease | |
| US11142522B2 (en) | Compounds, compositions and methods for cancer treatment | |
| JP2010132689A (ja) | ジヒドロピラゾロピリミジノン誘導体 | |
| US20230219965A1 (en) | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| PT2188291E (pt) | Pirimidinas bicíclicas fundidas | |
| RU2021114721A (ru) | Замещенные пиразолопиримидины и замещенные пурины и их применение в качестве ингибиторов убиквитин-специфической процессирующей протеазы 1 (usp1) | |
| TH2101003468A (th) | ไพราโซโลไพริมิดีนที่ถูกแทนที่และพิวรีนที่ถูกแทนที่และการใช้พวกมันในรูปของสารยับยั้งของโพรเซสซิ่งโปรตีเอสที่จำเพาะกับยูบิควิติน 1 (usp1) | |
| JP2018154620A5 (cg-RX-API-DMAC7.html) |